Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
105,337,747
-
Total 13F shares
-
105,289,941
-
Share change
-
+6,545,955
-
Total reported value
-
$2,320,227,206
-
Put/Call ratio
-
57%
-
Price per share
-
$22.00
-
Number of holders
-
190
-
Value change
-
+$130,326,516
-
Number of buys
-
98
-
Number of sells
-
100
Institutional Holders of Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX) as of Q1 2025
As of 31 Mar 2025 Edgewise Therapeutics, Inc. - Common Stock, par value $0.0001 per share (EWTX) had 190 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 105,289,941 shares of stock of the company.
Largest 10 holders included ORBIMED ADVISORS LLC, RA CAPITAL MANAGEMENT, L.P., PERCEPTIVE ADVISORS LLC, BlackRock, Inc., BAKER BROS. ADVISORS LP, Novo Holdings A/S, JANUS HENDERSON GROUP PLC, Paradigm Biocapital Advisors LP, VANGUARD GROUP INC, and Cormorant Asset Management, LP.
This table shows 190 institutional shareholders of the security as of 31 Mar 2025.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.